Biofrontera Past Earnings Performance
Past criteria checks 0/6
Biofrontera has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 1.5% per year.
Key information
1.7%
Earnings growth rate
4.3%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -1.5% |
Return on equity | -14.4% |
Net Margin | -11.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 22 | -3 | 11 | 8 |
31 Mar 24 | 30 | 0 | 12 | 8 |
31 Dec 23 | 32 | 0 | 13 | 8 |
30 Sep 23 | 29 | -9 | 13 | 8 |
30 Jun 23 | 28 | -11 | 13 | 8 |
31 Mar 23 | 25 | -20 | 13 | 7 |
31 Dec 22 | 26 | -44 | 12 | 7 |
30 Sep 22 | 32 | 11 | 18 | 7 |
30 Jun 22 | 31 | 10 | 24 | 7 |
31 Mar 22 | 30 | 15 | 29 | 7 |
31 Dec 21 | 29 | 38 | 34 | 7 |
30 Sep 21 | 28 | -16 | 28 | 6 |
30 Jun 21 | 27 | -16 | 29 | 5 |
31 Mar 21 | 29 | -12 | 26 | 5 |
31 Dec 20 | 30 | -13 | 28 | 5 |
30 Sep 20 | 33 | -17 | 33 | 5 |
30 Jun 20 | 33 | -22 | 37 | 5 |
31 Mar 20 | 31 | -10 | 45 | 5 |
31 Dec 19 | 31 | -7 | 44 | 5 |
30 Sep 19 | 26 | 1 | 44 | 4 |
30 Jun 19 | 26 | 8 | 40 | 5 |
31 Mar 19 | 23 | -8 | 33 | 5 |
31 Dec 18 | 21 | -9 | 31 | 4 |
30 Sep 18 | 19 | -14 | 24 | 4 |
30 Jun 18 | 16 | -15 | 22 | 4 |
31 Mar 18 | 14 | -16 | 21 | 4 |
31 Dec 17 | 12 | -16 | 20 | 4 |
30 Sep 17 | 11 | -18 | 21 | 5 |
30 Jun 17 | 9 | -16 | 17 | 5 |
31 Mar 17 | 8 | -14 | 14 | 5 |
31 Dec 16 | 6 | -11 | 12 | 5 |
30 Sep 16 | 4 | -9 | 9 | 4 |
30 Jun 16 | 4 | -7 | 8 | 4 |
31 Mar 16 | 4 | -9 | 7 | 6 |
31 Dec 15 | 4 | -11 | 7 | 6 |
30 Sep 15 | 4 | -12 | 7 | 7 |
30 Jun 15 | 3 | -13 | 7 | 7 |
31 Mar 15 | 3 | -10 | 7 | 5 |
31 Dec 14 | 3 | -11 | 7 | 5 |
30 Sep 14 | 3 | -10 | 7 | 4 |
30 Jun 14 | 3 | -10 | 7 | 4 |
31 Mar 14 | 3 | -9 | 6 | 4 |
31 Dec 13 | 3 | -8 | 5 | 3 |
Quality Earnings: B8FK is currently unprofitable.
Growing Profit Margin: B8FK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B8FK is unprofitable, but has reduced losses over the past 5 years at a rate of 1.7% per year.
Accelerating Growth: Unable to compare B8FK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B8FK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: B8FK has a negative Return on Equity (-14.38%), as it is currently unprofitable.